ArticleBMC cancer2025
Role of immediate injection of methylene blue after fiberoptic ductoscopy in selective ductectomy for patients with pathological nipple discharge.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microdochectomy for patients with nipple discharge and the risk of associated breast cancer.BMC surgery · 2026Article
- Advances and Opportunities in NIR-II Endoscopy: From Diagnosis to Therapeutic Applications.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposePathological nipple discharge (PND) is associated with malignancy. This study aimed to investigate the value of fiberoptic ductoscopy (FDS) and the feasibility of immediate injection of methylene blue after FDS to identify discharging ducts and intraductal lesions without overflow of methylene blue during surgery.
methodsFrom May 2019 to December 2023, 164 PND patients were enrolled. Methylene blue was injected into the discharging ducts immediately after FDS. Surgery was underwent several hours later. The dyeing effect and the operation time were assessed. The pathological results were analyzed with clinical characteristics and ductoscopic appearances.
resultsThe overall detection rate of malignancy was 14.0% (23/164). Both ultrasound (US) and mammography (MG) were negative in 80 (48.8%) patients, while pathology yielded 10 (12.5%) breast cancers. Statistical analysis revealed that patients exhibiting older age, menopause, positive MG, and bloody discharge had a higher propensity for malignancy (P < 0.05). Ductoscopic features such as multiple and distal lesions, irregular morphology and hemorrhage of the lesions, and roughness and stiffness of the ductal walls were associated with malignancy (P < 0.05). Conducting surgery 12-24 h after injection of methylene blue resulted in optimal dyeing without overflow of methylene blue.
conclusionFDS is an effective and feasible examination for PND patients with negative imaging results. Immediate injection of methylene blue after FDS allows clear identification of discharging ducts and intraductal lesions without overflow of methylene blue. This approach may be useful in guiding selective ductectomy for the detection of early breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.